Vertex Pharmaceuticals (VRTX) Net Equity Issued and Repurchased (2009)

Vertex Pharmaceuticals' (VRTX) quarterly Net Equity Issued and Repurchased came in at $488.1 million in Q4 2009, up 976300.0% quarter-over-quarter from -$50000.0 in Q2 2009.

Vertex Pharmaceuticals (VRTX) Net Equity Issued and Repurchased (2009) Analysis & Trends

Vertex Pharmaceuticals' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $488.1 million for Q4 2009.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $488.1 million in Q4 2009; TTM through Dec 2009 was $801.3 million, a N/A change from a year earlier, with the FY2009 full-year figure at $801.4 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased grew to $488.1 million in Q4 2009 per VRTX's latest filing, from -$50000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $488.1 million in Q4 2009 and bottomed at -$50000.0 in Q2 2009.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 141.90 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2009 488.10 Mn
Dec 31, 2009 488.10 Mn
Jun 30, 2009 -50,000.00
Jun 30, 2009 -50,000.00
Mar 31, 2009 313.30 Mn
Mar 31, 2009 313.30 Mn